The present study provides additional information underlying the pathogenic role of DNMT3A-MT with KMT2A-PTD in proliferating advantage with stem cell signature, enhanced self-renewal activity and aberrant HOXB expression in human leukemia, which may help to better understand the disease and to design better therapy for AML patients with these mutations. This evidence concerns the gene KMT2A and acute myeloid leukemia.